Aims: Transcatheter aortic valve implantation for a failing surgical bioprosthesis (TAV-in-SAV) has become an alternative for patients at high risk for redo surgical aortic valve replacem
Marco Spaziano1, MD; Darren Mylotte2, MD; Pascal Thériault-Lauzier1, MD, PhD; Ole De Backer3, MD, PhD; Lars Søndergaard3, MD, DMSc; Johan Bosmans4, MD, PhD; Nicolas Debry5, MD; Thomas Modine5, MD, PhD; Marco Barbanti6, MD; Corrado Tamburino6, MD, PhD; Jan-Malte Sinning7, MD, PhD; Eberhard Grube7, MD; Georg Nickenig7, MD; Fritz Mellert7, MD; Sabine Bleiziffer8, MD; Rüdiger Lange8, MD, PhD; Benoit de Varennes1, MD; Kevin Lachapelle1, MD; Giuseppe Martucci
1. McGill University Health Centre, Montreal, Canada; 2. Galway University Hospitals, Galway, Ireland; 3. Rigshospitalet, Copenhagen, Denmark; 4. University Hospital Antwerp, Antwerp, Belgium; 5. Centre Hospitalier Régional Universitaire de Lille, Lille,
Sign in to read and download the full articleForgot your password?
No account yet? Sign up for free!Create my pcr account
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
prior cardiovascular surgeryvalve-in-valvevalve restenosis
Read next articleTranscatheter aortic valve implantation for mixed versus pure stenotic aortic valve disease